E-Swin

E-Swin, founded in 2007, operates as a provider of flash lamp technology for the medical and aesthetic sectors. The company is headquartered in France and has undergone notable changes, including a significant acquisition by Ciclad and M Capital in May 2020. Igor Ponchio, the founder, has contributed to developing the company's vision, while Petra Bruckmüller currently serves as CEO. E-Swin has completed 3 deals to date, with its latest deal occurring on 2020-05-02.

E-Swin is a French leader in high technology flash lamps, specializing in innovative devices designed for the medical and aesthetic markets. Their core product offerings include the E-Eye, a pulsed light device specifically targeting dry eye syndrome and meibomian gland dysfunction (MGD), and the P-O75, which treats various pigmented lesions on the skin. The E-Eye is engineered to improve tear film quality and reduce symptoms associated with dry eyes, catering to patients suffering from both the evaporative and aqua-deficient forms of dry eye syndrome. The P-O75 device uses selective light filtration to target melanin in pigmented lesions, providing a non-invasive treatment solution.

E-Swin's products are distributed across significant international markets, including the United States, Australia, China, Brazil, and various European countries, serving a diverse clientele that spans healthcare professionals, clinics, and individual consumers. The company generates revenue through direct sales of its medical devices to healthcare providers, clinics, and aesthetic professionals, alongside partnerships with distributors in international markets. E-Swin’s focus on quality and compliance with international regulations, such as ISO 13485, assures buyers of product reliability and effectiveness, thereby fostering ongoing relationships and repeat business in the medical community. E-Swin is planning to launch new products targeting advancements in medical technology, aiming for a rollout by the end of 2024.

The company aims to expand its market presence in Asia and South America, focusing on further penetrating the healthcare sectors of these regions. The recent acquisition has strategically positioned E-Swin to utilize its newly acquired resources for these growth initiatives, enhancing product development and market outreach.